Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury.
Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury.
复制标题
DOI：
10.1002/ams2.622
复制
发表时间：
2021-01
影响因子：
1.6
通讯作者：
Tyndall JA
中科院分区：
文献类型：
--
作者：
Wang KKW;Kobeissy FH;Shakkour Z;Tyndall JA
创伤性脑损伤（TBI）是影响所有年龄段的死亡率和发病率的主要原因。这仍然是一个诊断和治疗的挑战，其中，迄今为止，没有食品和药物管理局批准的药物用于治疗TBI患者。疾病的异质性和相关的复杂病理生理学使得难以评估创伤的程度和预测临床结果。目前的损伤严重程度评估主要依赖于格拉斯哥昏迷量表评分或通过神经成像，包括磁共振成像和计算机断层扫描。然而，这种方法在准确性和成本效率方面具有一定的局限性，并且使患者暴露于不必要的辐射。因此，已经进行了广泛的研究工作，以提高TBI的诊断准确性，特别是在轻度损伤中，因为它们通常很难诊断。对准确和客观的诊断措施的需求导致了与TBI显著相关的生物标志物的发现。其中最充分表征的生物标志物是泛素C末端水解酶-L1和胶质细胞酸性蛋白。目前的审查提出了关于这些独特的蛋白质生物标志物的结构和功能的概述，沿着其临床意义，导致他们的批准，由美国食品和药物管理局评估轻度TBI患者。泛素C-末端水解酶-L1（UCH-L1）和胶质细胞酸性蛋白（GFAP）蛋白已被美国食品和药物管理局批准作为创伤性脑损伤的有前途的生物标志物。
Traumatic brain injury (TBI) is a major cause of mortality and morbidity affecting all ages. It remains to be a diagnostic and therapeutic challenge, in which, to date, there is no Food and Drug Administration‐approved drug for treating patients suffering from TBI. The heterogeneity of the disease and the associated complex pathophysiology make it difficult to assess the level of the trauma and to predict the clinical outcome. Current injury severity assessment relies primarily on the Glasgow Coma Scale score or through neuroimaging, including magnetic resonance imaging and computed tomography scans. Nevertheless, such approaches have certain limitations when it comes to accuracy and cost efficiency, as well as exposing patients to unnecessary radiation. Consequently, extensive research work has been carried out to improve the diagnostic accuracy of TBI, especially in mild injuries, because they are often difficult to diagnose. The need for accurate and objective diagnostic measures led to the discovery of biomarkers significantly associated with TBI. Among the most well‐characterized biomarkers are ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein. The current review presents an overview regarding the structure and function of these distinctive protein biomarkers, along with their clinical significance that led to their approval by the US Food and Drug Administration to evaluate mild TBI in patients. Ubiquitin C‐terminal hydrolase‐L1 (UCH‐L1) and glial fibrillary acidic protein (GFAP) proteins have been proposed as promising biomarkers for traumatic brain injury as approved by the US Food and Drug Administration.
登录
查看更多内容
DOI：
10.1074/jbc.m114.557124
发表时间：
2014-12-26
期刊：
The Journal of biological chemistry
影响因子：
--
作者：
Bishop P;Rubin P;Thomson AR;Rocca D;Henley JM
通讯作者：
Henley JM
影响因子：
48
作者：
Bazarian, Jeffrey J.;Biberthaler, Peter;Jagoda, Andy S.
通讯作者：
Jagoda, Andy S.
影响因子：
4.8
作者：
Choi, J;Levey, AI;Li, L
通讯作者：
Li, L
影响因子：
4.2
作者：
Brophy, Gretchen M.;Mondello, Stefania;Wang, Kevin K. W.
通讯作者：
Wang, Kevin K. W.
DOI：
10.2217/cnc-2017-0019
发表时间：
2018-03-01
期刊：
Concussion (London, England)
影响因子：
--
作者：
Dadas, Aaron;Janigro, Damir
通讯作者：
Janigro, Damir